Length:
111 pages

Date Published:September 2010

Print copies are available upon request. Call 781-972-5444. 

For Corporate Subscriptions, Multi-Reports Orders, Discounts or Order Questions.  

Contact:
Kerri Kelley
Customer Service
781-972-1347 



Nuclear Receptors: The Pipeline Outlook Report - Table of Contents

Author: Mark Via

EXECUTIVE SUMMARY

CHAPTER 1
BACKGROUND AND SCIENTIFIC OVERVIEW: THE FUNCTION AND CLASSIFICATION OF NUCLEAR RECEPTORS
1.1. The Functions and Mechanisms of Nuclear Receptors
1.2. Classifying Nuclear Receptors

CHAPTER 2
NUCLEAR RECEPTORS AND DISEASE: DEFINING PHARMACEUTICAL TARGETS
2.1. Overview
2.2. Thyroid Hormone Receptor-like Subfamily

TR - thyroid hormone receptors
RAR - retinoic acid receptors
PPAR - peroxisome proliferator-activated receptors
Rev-erb and ROR - retinoic acid receptor-related orphan receptors
LXR - liver x receptor and FXR - farnesoid x receptor
VDR - vitamin D receptor-like Group
PXR - pregnane X receptor
2.3. Retinoid X Receptor-like Subfamily
HNF4 - hepatocyte nuclear factor-4-alpha receptor
RXR - retinoid X receptors
TR2 and TR4 - testicular receptors
TLX - Drosophila tailless receptor and PNR - photoreceptor cell-specific nuclear receptor
COUP-TF - chicken ovalbumin upstream promoter-transcription factor
2.4. Estrogen Receptor-like Subfamily
ER - estrogen receptor and ERR - estrogen-related receptors
GR - glucocorticoid receptor
MR ­- mineralocorticoid receptor
PR - progesterone receptor
AR - androgen receptor
2.5. Nerve Growth Factor-IB-like Subfamily
2.6. Steroidogenic Factor-like Subfamily

SF1
LRH1
2.7. GCNF
2.8. Miscellaneous Receptors

DAX1
SHP

CHAPTER 3
DRUGS IN DEVELOPMENT: THE POTENTIAL IN MODULATING NUCLEAR RECEPTORS
3.1. Thyroid Hormone Receptor-like Subfamily
TR
Karo Bio
QuatRx Pharmaceuticals
Ligand Pharmaceuticals
VIA Pharmaceuticals
RAR
Roche
GlaxoSmithKline
Galderma Pharma
Allergan
Cipher Pharmaceuticals
Phosphagenics
CytRx/Zeria Pharmaceutical
Other RAR Modulators for Cancer
PPAR
Dr. Reddy’s Laboratories/Nordic Bioscience
Roche
InteKrin Therapeutics
Metabolex
Plexxikon
Kalypsys
DARA BioSciences
Cerenis Therapeutics/Nippon Chemiphar
SRI International
Omeros
Others
ROR
Orphagen Pharmaceuticals
LXR and FXR
Intercept Pharmaceuticals
Exelixis/Bristol-Myers Squibb/Pfizer
Phenex Pharmaceuticals
Poxel
Pfizer/Karo Bio
Vitamin D Receptor-like Group
Chugai Pharmaceutical/Taisho Pharmaceutical
Cytochroma
Galderma Pharma/QuatRx Pharmaceuticals/Deltanoid Pharmaceuticals
Hybrigenics
Dermipsor
Johnson & Johnson
Marillion Pharmaceuticals
Bayer Schering Pharma
3.2. Retinoid X Receptor-like Subfamily
RXR
Basilea Pharmaceutica
3.3. Estrogen Receptor-like Subfamily
ER
Pfizer/Ligand Pharmaceuticals
QuatRx Pharmaceuticals
GTx/Ipsen
Adeona Pharmaceuticals
Pantarhei Bioscience
Ascend Therapeutics
Radius
Karo Bio/Merck
Repros Therapeutics
Bionovo
Chiesi Pharmaceuticals
Ausio Pharmaceuticals
Shenogen
PepTcell
Acadia Pharmaceuticals
Yeda Research and Development
Aragon Pharmaceuticals
GR
Corcept Therapeutics
CyDex Pharmaceuticals
OptiNose
Bayer Schering Pharma
CombinatoRx/Fovea Pharmaceuticals
Lithera
Foresight Biotherapeutics
EyeGate Pharmaceuticals
Otonomy
NicOx/Grupo Ferrer Internacional
Novagali Pharma
Karo Bio/Zydus Cadila
Isis Pharmaceuticals/Ortho-McNeil-Janssen Pharmaceuticals
Sun Pharma
Clavis Pharma
Others
MR
Exelixis/Daiichi Sankyo
Canopus BioPharma
PR
HRA Pharma/PregLem
Repros Therapeutics
Bayer Schering Pharma
NeuroScience Pharmaceuticals
Others
AR
Medivation/Astellas Pharma
Cosmo Pharmaceuticals
GTx/Merck
Harbor Biosciences
Tokai Pharmaceuticals
Ligand Pharmaceuticals
Pantarhei Bioscience
Radius
Adamis Pharmaceuticals/Colby Pharmaceuticals
Galapagos
Aragon Pharmaceuticals
Chugai Pharmaceutical
Enzon Pharmaceuticals/Santaris Pharma
Serometrix
Orion
3.4. Nerve Growth Factor-IB-like Subfamily
3.5. Steroidogenic Factor-like Subfamily

SF1
Orphagen Pharmaceuticals
LRH1
3.6. Miscellaneous Receptors
SHP
Pfizer

CHAPTER 4
FUTURE DIRECTIONS IN DRUG DEVELOPMENT

CHAPTER 5
LANDSCAPE
5.1. The Blockbusters
5.2. Current Nuclear Receptor Drug Franchises
5.3. The Nuclear Receptor-Targeted Drugs Pipeline
5.4. Leading Nuclear Receptor-Targeted Compounds
5.5. Comparison of Nuclear Receptor Targets and Indications for Launched Drugs and Pipeline Candidates
5.7. Where is the Development Activity Concentrated?
5.8. Summary

REFERENCES

COMPANY INDEX WITH WEB ADDRESSES